Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 320
- Registration Number
- NCT02450656
- Locations
- 🇳🇱
UMC St. Radboud Nijmegen, Nijmegen, Gelderland, Netherlands
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- Conditions
- Interventions
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT02407405
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
- Conditions
- Stage IV Thyroid Gland Follicular Carcinoma AJCC v7Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7Recurrent Thyroid Gland CarcinomaStage IV Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7Metastatic Thyroid Gland Carcinoma
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 60
- Registration Number
- NCT02393690
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 62
- Registration Number
- NCT02337530
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- Drug: AZD2014Drug: AnthracyclinesDrug: MEDI4736Drug: AZD4547Drug: TaxanesDrug: AZD5363Drug: cyclophosphamideDrug: DNA intercalatorsDrug: AZD8931Drug: SelumetinibDrug: MethotrexateDrug: vinca alkaloidsDrug: VandetanibDrug: Platinum based chemotherapiesDrug: BicalutamideDrug: OlaparibDrug: BevacizumabDrug: Mitomycin CDrug: Eribulin
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT02188264
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 57
- Registration Number
- NCT02151084
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 999
- Registration Number
- NCT02117167
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Paoli Calmettes, Marseille, France
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT02093728
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT02063204
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.